Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke

• Status: Completed
• Trial end date: 2019-10-31
• Target enrollment: 0
• Participant gender: All

Summary

Cerebrovascular disease is the main cause of death and severe long-term disability worldwide. Antiplatelet drugs are the main drugs for ischemic stroke and TIA. Cyclooxygenase inhibitor acetylsalicylic acid (ASA) has always been the most widely studied antiplatelet therapy. The studies of acrates of aliscon body evaluated the efficacy and safety of ticagrelor monotherapy in preventing major vascular events in patients with AIS or TIA. The results showed that the number of patients with endpoint events in ticagrelor group was less than that in ASA group, However, it has not been proved that ticagrelor monotherapy is better than ASA. The purpose of this study is to prove that ticagrelor is better than ASA.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University Third Hospital
• Collaborator: AstraZeneca Investment (China) Co., Ltd
• Treatments: Ticagrelor

Criteria

Inclusion Criteria:

1. Over 40 years old

2. Acute ischemic attack

3. Symptoms occurred within 24 hours after randomization

Exclusion Criteria:

1. Dual antiplatelet therapy with ASA and P2Y12 inhibitors is needed

2. Antiplatelet agents other than ASA

3. Anticoagulant therapy

4. Have any atrial fibrillation / flutter

5. Renal failure requiring dialysis

6. During pregnancy or lactation